Source: JAC Antimicrob Resist. Unidade: FCF
Subjects: STAPHYLOCOCCUS, STREPTOCOCCUS, RESISTÊNCIA MICROBIANA ÀS DROGAS
ABNT
CASTILLO, María García et al. In vitro activity of ozenoxacin against Staphylococcus aureus and Streptococcus pyogenes clinical isolates recovered in a worldwide multicentre study (2020–2022). JAC Antimicrob Resist, v. 6, p. 1-9, 2024Tradução . . Disponível em: https://dx.doi.org/10.1093/jacamr/dlae088. Acesso em: 14 nov. 2024.APA
Castillo, M. G., García, M. H., Correa, A., Coppi, M., Griener, T., Fritsche, T., et al. (2024). In vitro activity of ozenoxacin against Staphylococcus aureus and Streptococcus pyogenes clinical isolates recovered in a worldwide multicentre study (2020–2022). JAC Antimicrob Resist, 6, 1-9. doi:10.1093/jacamr/dlae088NLM
Castillo MG, García MH, Correa A, Coppi M, Griener T, Fritsche T, Pitart C, Sampaio JLM, Seifert H, Wake K, Wootton M, Vila J, Cantón R. In vitro activity of ozenoxacin against Staphylococcus aureus and Streptococcus pyogenes clinical isolates recovered in a worldwide multicentre study (2020–2022) [Internet]. JAC Antimicrob Resist. 2024 ; 6 1-9.[citado 2024 nov. 14 ] Available from: https://dx.doi.org/10.1093/jacamr/dlae088Vancouver
Castillo MG, García MH, Correa A, Coppi M, Griener T, Fritsche T, Pitart C, Sampaio JLM, Seifert H, Wake K, Wootton M, Vila J, Cantón R. In vitro activity of ozenoxacin against Staphylococcus aureus and Streptococcus pyogenes clinical isolates recovered in a worldwide multicentre study (2020–2022) [Internet]. JAC Antimicrob Resist. 2024 ; 6 1-9.[citado 2024 nov. 14 ] Available from: https://dx.doi.org/10.1093/jacamr/dlae088